Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

By David A Henry, P. Carless, A. Moxey, D. O'Connell, Barrie J Stokes, B. McClelland, A. Laupacis, Dean A. Fergusson. Cochrane Database of Systematic Reviews, 2007

1,049 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/25d7a351a55b9cfbc2988824038dceef7cedb946

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Yancy
2. L. Hiratzka
3. Rick A. Nishimura
4. T. Wainwright
5. M. Gill
6. D. McDonald
7. R. Bersin
8. R. Middleton

Citations in the corpus

• Management of bleeding following major trauma: an updated European guideline (2010, background): “acid has been of major theoretical concern; however, the Cochrane review of antifibrinolytics cites studies that included more than 8,000 patients receiving lysine analogues and demonstrated no increased risk of either arterial or venous thrombotic events [307].”
• Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease (2010, background): “0 mg/kg/h delivered over 1 to 12 hours (657).”
• Consensus statement for perioperative care in total hip replacement and total knee replacement surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations (2019, background): “Studies have found it to be both efficient and safe (Rajesparan et al. 2009, Husted et al. 2010, 2014, Henry et al. 2011) despite previous concerns of an increased risk of venous thromboembolic events; and recent RCTs and metaanalyses support combined systemic and/or intra-articular administration…”